Fig. 4

WWP2 inhibits endothelial injury in vitro. A, F The proliferation and viability of HUVECs was tested using the CCK-8 colorimetric assay. HUVECs were transfected with HA-WWP2 plasmid (A) or WWP2 siRNA (F) and treated with or without HG/PA for 48 h. B, C, G, H Representative Flow cytometry analysis (B, G) and quantitative analysis (C, H) of apoptosis in HUVECs transfected with HA-WWP2 plasmid (B, C) or WWP2 siRNA (G, H) and treated with or without HG/PA for 48 h. D, E, I, J Representative Western blots (D, I) and quantification (E, J) of HA-WWP2, WWP2, Cleaved PARP1 and Cleaved caspase-3 protein expression levels in vitro. HUVECs were transfected with HA-WWP2 plasmid (D, E) or WWP2 siRNA (I, J) and treated with or without HG/PA for 48 h. Values are shown as mean ± SD (**P < 0.01, ***P < 0.001, ##P < 0.01, ###P < 0.001, NS = not significant, two-way ANOVA with Bonferroni’s multiple comparison post hoc test). CCK-8, Cell Counting Kit-8; Ctrl, control; HG/PA, high glucose/palmitic acid; HUVECs, HUVECs, Human umbilical vein endothelial cells; NC, negative control; siRNA, small interfering RNA